NDA 203496 · United Therap
Orenitram
Treprostinil Diolamine · Oral · Prostacycline Vasodilator
OrphanLast checked: Nov 20, 2026Latest source record: Aug 4, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Dec 20, 2013
Approved uses
3
Original approval plus efficacy supplements
Registered trials
8
6 Phase 3, 0 recruiting
FAERS reports
26,071
14,330 serious, 2,475 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 20, 2024.
Orenitram is a prostacyclin mimetic indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): To delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%). ( 1.1 ) 1.1 Pulmonary Arterial Hypertension Orenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%).
Mechanism: The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds, inhibition of platelet aggregation, and inhibition of smooth muscle cell proliferation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 18, 2019 Supplement 11 · Efficacy OrphanLabelLetter
- Jan 28, 2016 Supplement 2 · Efficacy OrphanLabelLetter
- Dec 20, 2013 Original approval · Type 3 - New Dosage Form OrphanLabelReviewSummary Review
5 products under this application
- ORENITRAM · TREPROSTINIL DIOLAMINE EQ 5MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
- ORENITRAM · TREPROSTINIL DIOLAMINE EQ 1MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
- ORENITRAM · TREPROSTINIL DIOLAMINE EQ 0.125MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
- ORENITRAM · TREPROSTINIL DIOLAMINE EQ 2.5MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
- ORENITRAM · TREPROSTINIL DIOLAMINE EQ 0.25MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Treprostinil Diolamine" as an intervention, any sponsor and status, largest first.
- An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial HypertensionPivotal-lookingCompleted
United TherapeuticsIndustry
NCT01027949 · 894 participants · Start Jan 16, 2007 · Primary completion Feb 12, 2020
Drug: Oral Treprostinil · For: Pulmonary Arterial Hypertension
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 134 sites in all
- Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral MonotherapyPivotal-lookingCompleted
United TherapeuticsIndustry
NCT01560624 · 690 participants · Start Jun 26, 2012 · Primary completion Jun 24, 2018
Drug: Treprostinil Diolamine; Placebo · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; Tucson, Arizona; Fresno, California · 155 sites in all
- An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial HypertensionPivotal-lookingCompleted
United TherapeuticsIndustry
NCT01560637 · 471 participants · Start Sep 11, 2013 · Primary completion Aug 12, 2021
Drug: UT-15C (treprostinil diolamine) · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; Tucson, Arizona; Fresno, California · 153 sites in all
- Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial HypertensionPivotal-lookingCompleted
United TherapeuticsIndustry
NCT00887978 · 310 participants · Start Jun 2009 · Primary completion Jul 2011
Drug: UT-15C SR; Placebo · For: Pulmonary Hypertension
Sites: Birmingham, Alabama; Phoenix, Arizona; Fresno, California · 62 sites in all
- Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection FractionPivotal-lookingTerminated
United TherapeuticsIndustry
NCT03037580 · 84 participants · Start Aug 15, 2017 · Primary completion Dec 3, 2019
Drug: Oral treprostinil; Placebo · For: Pulmonary Hypertension; Heart Failure With Preserved Ejection Fraction
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 82 sites in all
- Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEFPivotal-lookingTerminated
United TherapeuticsIndustry
NCT03043651 · 48 participants · Start Jan 30, 2018 · Primary completion Mar 2, 2020
Drug: Oral treprostinil · For: Pulmonary Hypertension Associated With HFpEF
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 82 sites in all
- Three Times Daily Dosing of UT-15CCompleted
United TherapeuticsIndustry
NCT01746485 · 19 participants · Start Jul 2012 · Primary completion Jul 2012
Drug: UT-15C · For: Healthy
Sites: Austin, Texas
Mardi Gomberg -Maitland MD, MScAcademic, hospital or other
NCT04882774 · 0 participants · Start Apr 2023 · Primary completion Apr 2025
Drug: Treprostinil Diolamine · For: Pulmonary Hypertension Due to Left Heart Disease
Sites: Washington D.C., District of Columbia; Columbus, Ohio; Pittsburgh, Pennsylvania
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- headache5,649
- diarrhoea4,908
- dyspnoea4,709
- nausea4,246
- fatigue2,600
- dizziness2,342
- vomiting2,190
- pain in extremity1,710
- flushing1,707
- hypotension1,516
- malaise1,509
- pain1,460
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 8 |
| 2010 | 13 |
| 2011 | 23 |
| 2012 | 41 |
| 2013 | 43 |
| 2014 | 386 |
| 2015 | 1,322 |
| 2016 | 1,826 |
| 2017 | 1,926 |
| 2018 | 2,198 |
| 2019 | 2,126 |
| 2020 | 2,001 |
| 2021 | 2,159 |
| 2022 | 2,381 |
| 2023 | 2,573 |
| 2024 | 2,241 |
| 2025 | 2,814 |
| 2026 | 1,983 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension.
White RJ, Torres F, Allen R, et al. · J Cardiovasc Pharmacol 2013 · Clinical Trial, Phase III, Multicenter Study
- Lack of a pharmacokinetic interaction between treprostinil diolamine and sildenafil in healthy adult volunteers.
Gotzkowsky SK, Kumar P, Mottola D, et al. · J Cardiovasc Pharmacol 2013 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Pharmacokinetics of treprostinil diolamine in subjects with end-stage renal disease on or off dialysis.
Jenkins A, Wang-Smith L, Marbury T, et al. · J Cardiovasc Pharmacol 2013 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- The effect of different meal compositions on the oral bioavailability of treprostinil diolamine in healthy volunteers.
Lim A, Wang-Smith L, Kates J, et al. · J Clin Pharm Ther 2013 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers.
Jones A, Wang-Smith L, Pham T, et al. · J Cardiovasc Pharmacol 2014 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1).
Mecoli CA, Perin J, Van Eyk JE, et al. · Clin Rheumatol 2020 · Clinical Trial, Phase II, Multicenter Study
Sponsor: United Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.